ClinicalTrials.gg
RecruitingNCT06300008Updated Mar 8, 2024

Cetylated Fatty Acid for Reducing Pain After TKA

An interventional study of cetylated fatty acid and Placebo in Postoperative Pain and Postoperative Inflammation, sponsored by Thammasat University. Recruiting at 1 site in Thailand. Open to participants aged 50 Years to 80 Years. Per ClinicalTrials.gov, last updated 2024-03-08.

Sponsored by Thammasat University · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by Sep 2024, 2 years 2 months ago, but the record still lists the study as recruiting.
  • Started Feb 2024; still recruiting 2 years 9 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
80
Allocation
Randomized
Ages
50 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 11 studies in Pain, Postoperative by Thammasat University — 2 open to participants now, 2 under way, none of them phase 3. Pain, Postoperative · Thammasat University.

Planned enrollment
6th of 10
80 · median 90
Started
2024
the only one that year
No phase
4 of 11
1 open now
Registered
9th of 11
by date

Among the 11 studies in Pain, Postoperative by Thammasat University, this one is the 6th largest by planned enrollment of the 10 interventional ones that give a count, is the only one that started in 2024, is one of 4 with no phase, and was the 9th registered.

Pain, Postoperative

5,680 studies on the registry are indexed under Pain, Postoperative; 1,243 are open to participants now.

Browse Pain, Postoperative studies →

Open to participants now

2 of the 11 studies in Pain, Postoperative by Thammasat University are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

Where they have run

Who these studies take

Of the 678 Pain, Postoperative studies recruiting now, 239 (35%) set no upper age limit and 329 (49%) stop at 75 or younger; 74 take children under 18; 129 take healthy volunteers.

This study: 50 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 11 studies in Pain, Postoperative by Thammasat University, or all of them as a file.
02

Study summary

To compare efficacy of cetylated fatty acid with placebo for reducing postoperative pain after unilateral TKA. The hypothesis is topical cetylated fatty acid can mitigate postoperative pain after TKA.

03

Conditions studied

  • Postoperative Pain
  • Postoperative Inflammation

Keywords

  • Cetylated fatty acid
  • TKA
  • Postoperative pain
  • Inflammation
04

Who can participate

Ages eligible
50 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age 50-80 years
  • Osteoarthritic knee patients underwent unilateral primary TKA
  • Participants understand and consent to the protocol of the trial

Exclusion criteria

Exclusion Criteria:

  • Inflammatory knee arthritis
  • Previous knee surgery or trauma
  • Previous knee infection
  • Skin problem around the knee such as eczema, psoriasis, wound infection
  • Allergy to studied drug
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
80 participants (estimated)

Study arms

  • Experimental
    cetylated fatty acid

    Topical cetylated fatty acid, apply 2 times/day for 6 weeks after operation

    Drug: cetylated fatty acid

  • Placebo comparator
    Placebo

    Topical placebo, apply 2 times/day for 6 weeks after operation

    Drug: Placebo

Interventions

  • Drugcetylated fatty acid

    use approximately 3 cm long of cream per each side of knee, then apply on the operated knee until completely absorb

    Also known as: Cetilar

  • DrugPlacebo

    use approximately 3 cm long of cream per each side of knee, then apply on the operated knee until completely absorb

06

What researchers measure

Primary outcomes

  1. Visual analog scale

    VAS (0-100) at rest and on motion

    Time frame: post-op Day2

  2. Visual analog scale

    VAS (0-100) at rest and on motion

    Time frame: post-op week2

  3. Visual analog scale

    VAS (0-100) at rest and on motion

    Time frame: post-op week6

  4. Visual analog scale

    VAS (0-100) at rest and on motion

    Time frame: post-op week12

  5. inflammatory marker

    ESR and CRP

    Time frame: post-op day2

  6. inflammatory marker

    ESR and CRP

    Time frame: post-op week2

  7. inflammatory marker

    ESR and CRP

    Time frame: post-op week6

  8. inflammatory marker

    ESR and CRP

    Time frame: post-op week12

  9. Knee skin temperature

    evaluated by digital infrared thermometer at 4 different locations on the anterior aspect of the knee independently (superomedial, superolateral, inferomedial, inferolateral borders of the patella) compared with the contralateral knee

    Time frame: post-op Day2

  10. Knee skin temperature

    evaluated by digital infrared thermometer at 4 different locations on the anterior aspect of the knee independently (superomedial, superolateral, inferomedial, inferolateral borders of the patella) compared with the contralateral knee

    Time frame: post-op week2

  11. Knee skin temperature

    evaluated by digital infrared thermometer at 4 different locations on the anterior aspect of the knee independently (superomedial, superolateral, inferomedial, inferolateral borders of the patella) compared with the contralateral knee

    Time frame: post-op week6

  12. Knee skin temperature

    evaluated by digital infrared thermometer at 4 different locations on the anterior aspect of the knee independently (superomedial, superolateral, inferomedial, inferolateral borders of the patella) compared with the contralateral knee

    Time frame: post-op week12

Secondary outcomes

  1. Knee circumference (cm)

    Measured by tape at midpoint of patella

    Time frame: post-op Day2

  2. Knee circumference (cm)

    Measured by tape at midpoint of patella

    Time frame: post-op week2

  3. Knee circumference (cm)

    Measured by tape at midpoint of patella

    Time frame: post-op week6

  4. Knee circumference (cm)

    Measured by tape at midpoint of patella

    Time frame: post-op week12

  5. Knee Range of Motion

    Flexion and extension angle

    Time frame: post-op Day2

  6. Knee Range of Motion

    Flexion and extension angle

    Time frame: post-op week2

  7. Knee Range of Motion

    Flexion and extension angle

    Time frame: post-op week6

  8. Knee Range of Motion

    Flexion and extension angle

    Time frame: post-op week12

  9. Modified WOMAC

    Total \& Subscore

    Time frame: post-op week2

  10. Modified WOMAC

    Total \& Subscore

    Time frame: post-op week6

  11. Modified WOMAC

    Total \& Subscore

    Time frame: post-op week12

  12. Thai forgotten joint score

    Time frame: post-op week2

  13. Thai forgotten joint score

    Time frame: post-op week6

  14. Thai forgotten joint score

    Time frame: post-op week12

07

Study locations

1 of 1 sites recruiting
  • department of orthopaedic surgery, Faculty of medicine, Thammasat university
    Khlong Luang, Pathumthani 066, Thailand
    Recruiting
    • supakit kanitnate · Contactnaypeng@hotmail.com · 6629260000
    • Nattapol Tammachote, M.D. · Principal investigator
    • Supakit Kanitnate, M.D. · Sub investigator
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Feb 2024 (actual). Primary completion is estimated for Sep 2024, 7 months after the start.

Of 2,113 non-industry interventional studies with no phase under Pain, Postoperative, half reached primary completion within 11 months of starting (the median), counting those still running; a quarter within 6 and three quarters within 23. This study's planned 7 months is below that.

Counting every sponsor, half of 2,126 studies reached it within 11 months; a quarter within 6 and three quarters within 23.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 24, 2022
First posted
Mar 8, 2024
StartActual
Feb 12, 2024
Primary completionEst.
Sep 2024
CompletionEst.
Dec 2024
Last update
Mar 8, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 8, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06300008
Lead sponsor
Thammasat University
Responsible party
Supakit Kanitnate (Principle investigator, Thammasat University) — Principal investigator
First posted
Mar 8, 2024
Start date
Feb 12, 2024
Primary completion
Sep 2024 (estimated)
Completion
Dec 2024 (estimated)
Last update
Mar 8, 2024

Study contacts

Supakit Kanitnate, M.D.
Contact
naypeng@hotmail.com
66899853635
Supakit Kanitnate, MD
principal investigator · Thammasat University Hospital

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion